[Expression of CD44, CD87 and CD123 in Acute Leukemia and Its Correlation with Cellular Immunity]
Shu-Wen Wang1, Hong-Xia Yao1, Ruo Rao2
1Department of Hematology, Hainan Provincial People's Hospital, Haikou 570000, Hainan Provivnce, China
Insights
The expression of CD44, CD87, and CD123 cells differs across acute leukemia phenotypes and correlates with patient prognosis. Higher expression of CD44 and CD87 indicates a poorer prognosis in acute leukemia patients.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Acute leukemia (AL) is a heterogeneous group of cancers.
- Understanding cellular immune markers in AL is crucial for prognosis.
Purpose of the Study:
- To investigate the differential expression of CD44, CD87, and CD123 in various acute leukemia phenotypes.
- To determine the correlation between these markers and patient prognosis.
Main Methods:
- Three-color flow cytometry was used to analyze CD44, CD87, and CD123 expression in 166 AL patients and 50 controls.
- Expression levels were correlated with treatment response (Complete Remission - CR vs. Partial Remission/No Remission - PR+NR) and prognosis using SPSS Pearson correlation analysis.
Main Results:
- Positive rates of CD44, CD87, and CD123 were significantly higher in AL patients compared to controls (P<0.05).
- Specific expression patterns varied between acute myeloid leukemia, acute lymphoblastic leukemia, and B/myeloid phenotypes.
- Higher CD44, CD87, and CD123 expression was observed in patients with poorer treatment outcomes (PR+NR) compared to CR patients (P<0.05).
- Prognosis negatively correlated with CD44 and CD87 expression (P<0.05).
Conclusions:
- CD44, CD87, and CD123 expression levels differ among acute leukemia phenotypes and are associated with patient prognosis.
- These markers can serve as valuable indicators for evaluating prognosis and guiding clinical treatment decisions in acute leukemia.
Objective:
To investigate the expression of CD44, CD87 and CD123 in acute leukemia and its correlation with cellular immune markers.
Methods:
A total of 166 patients with acute leukemia (AL) admitted from May 2014 to February 2017 were enrolled in AL groups. Among these patients, 100 patients suffered from acute myeloid leukemia, 50 patients suffered from acute lymphoid leukemia, and 16 patients showed B/medullary phenotype. At the same time 50 patients with non-acute leukemia were enrolled in the control group. 5 ml of fasting venous blood collected from the patients in each group, and the percentage of CD44, CD87 and CD123 cells was determined by three-color flow cytometry. Symptomatic chemotherapy was given to the patients with confirmed acute leukemia, and the remission was evaluated after 2 treatmen courses. The Complete remission (CR) was recorded and the percentage of CD44, CD87 and CD123 cells under different curative efficacy were recorded. The correlation of the prognosis patients with CD44, CD87 and CD123 was analyzed by SPSS Pearson correlation analysis software.
Results:
The positive rates of CD44, CD87 and CD123 in AL group were all higher than those in the control group (P＜0. 05). The positive rates of CD44 and CD123 in acute myeloid leukemia group were higher than those in acute lymphoblastic leukemia group and B/myeloid phenotype group (P＜0. 05). The positive rate of CD44 in acute lymphoid leukemia group was higher than that in B/medullary double phenotype group (P＜0.05). The treatment in the patients of AL group was successfully completed. 132 patients reachel to CR and 34 patients to PR+NR after 2 courses. The positive rates of CD44, CD87 and CD123 in CR patients were lower than those in PR+NR patients (P＜0.05). The results of SPSS Pearson correlation analysis showed that the prognosis of patients with acute leukemia negatively correlated with CD44 and CD87 (P＜0.05).
Conclusion:
The expression of CD44, CD87 and CD123 in different phenotype of acute leukemia are different, which correlateds with prognosis. The determination of CD44, CD87 and CD123 can be used to evaluate the prognosis of patients for the reference of clinical treatment.
More Related Videos
05:24Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
Published on: February 21, 2021
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Related Concept Videos
01:27Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
01:22T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...